Patents by Inventor Ulf Neumann

Ulf Neumann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oxazine Derivative for Use in the Prevention of Alzheimer's Disease in at Risk Patents
    Publication number: 20200345746
    Abstract: The present invention relates to an oxazine derivative BACE-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the prevention of Alzheimer's disease in a patient at risk of developing clinical symptoms of Alzheimer's disease, and in particular, wherein the patient at risk of developing clinical symptoms of Alzheimer's disease carries one or two copies of the ApoE4 allele.
    Type: Application
    Filed: July 17, 2020
    Publication date: November 5, 2020
    Inventors: Cristina LOPEZ-LOPEZ, Ulf NEUMANN
  • Oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy
    Patent number: 10722518
    Abstract: The present invention relates to an oxazine derivative BACE-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy and, in particular, wherein the patient carries one or two copies of the ApoE4 allele.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: July 28, 2020
    Assignee: Novartis AG
    Inventors: Cristina Lopez-Lopez, Ulf Neumann, Derya Shimshek
  • TREM2 MUTANTS RESISTANT TO SHEDDASE CLEAVAGE
    Publication number: 20200207830
    Abstract: Provided herein are methods and compositions related to TREM2 mutants resistant to sheddase cleavage, e.g., human TREM2 mutants resistant to sheddase cleavage, and nucleic acids encoding such TREM2 mutants resistant to sheddase cleavage.
    Type: Application
    Filed: July 26, 2018
    Publication date: July 2, 2020
    Inventors: Dominik FEUERBACH, Ulf NEUMANN
  • OXAZINE DERIVATIVE FOR USE IN THE TREATMENT OR PREVENTION OF CEREBRAL AMYLOID ANGIOPATHY
    Publication number: 20180125853
    Abstract: The present invention relates to an oxazine derivative BACE-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy and, in particular, wherein the patient carries one or two copies of the ApoE4 allele.
    Type: Application
    Filed: October 11, 2017
    Publication date: May 10, 2018
    Inventors: Cristina LOPEZ-LOPEZ, Ulf NEUMANN, Derya SHIMSHEK
  • Oxazine Derivative for Use in the Prevention of Alzheimer's Disease in at Risk Patients
    Publication number: 20180036315
    Abstract: The present invention relates to an oxazine derivative BACE-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the prevention of Alzheimer's disease in a patient at risk of developing clinical symptoms of Alzheimer's disease, and in particular, wherein the patient at risk of developing clinical symptoms of Alzheimer's disease carries one or two copies of the ApoE4 allele.
    Type: Application
    Filed: July 17, 2017
    Publication date: February 8, 2018
    Inventors: Cristina LOPEZ-LOPEZ, Ulf NEUMANN
  • OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
    Publication number: 20150018338
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.
    Type: Application
    Filed: July 7, 2014
    Publication date: January 15, 2015
    Applicant: NOVARTIS AG
    Inventors: Sangamesh BADIGER, Murali CHEBROLU, Mathias FREDERIKSEN, Philipp HOLZER, Konstanze HURTH, Rainer Martin LEUOEND, Rainer MACHAUER, Henrik MOEBITZ, Ulf NEUMANN, Rita RAMOS, Henrich RUEEGER, Michael SCHAEFER, Marina TINTELNOT-BLOMLEY, Siem Jacob VEENSTRA, Markus VOEGTLE
  • Oxazine Derivatives and their Use in the Treatment of Neurological Disorders
    Publication number: 20130281449
    Abstract: The invention relates to novel heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, in free form or in pharmaceutically acceptable salt form, to their preparation, to their medical use and to medicaments comprising them.
    Type: Application
    Filed: January 11, 2012
    Publication date: October 24, 2013
    Applicant: NOVARTIS AG
    Inventors: Konstanze Hurth, Rainer Martin Lueoend, Rainer Machauer, Ulf Neumann, Heinrich Rueeger, Michael Schaefer, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle
  • OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
    Publication number: 20120302558
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.
    Type: Application
    Filed: July 13, 2011
    Publication date: November 29, 2012
    Inventors: Sangamesh Badiger, Murali Chebrolu, Mathias Frederiksen, Philipp Holzer, Konstanze Hurth, Rainer Martin Lueoend, Rainer Machauer, Henrik Moebitz, Ulf Neumann, Rita Ramos, Heinrich Rueeger, Michael Schaefer, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle, Lei Li, Hui Liu, Xin Xiong
  • Oxazine Derivatives and their Use in the Treatment of Neurological Disorders
    Publication number: 20120172359
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.
    Type: Application
    Filed: March 7, 2012
    Publication date: July 5, 2012
    Applicant: NOVARTIS AG
    Inventors: Sangamesh BADIGER, Murali CHEBROLU, Mathias FREDERIKSEN, Philipp HOLZER, Konstanze HURTH, Rainer Martin LUEOEND, Lei LI, Hui LIU, Rainer MACHAUER, Henrik MOEBITZ, Ulf NEUMANN, Rita RAMOS, Heinrich RUEEGER, Michael SCHAEFER, Siem Jacob VEENSTRA, Marina TINTELNOT-BLOMLEY, Markus VOEGTLE, Xin XIONG
  • OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
    Publication number: 20110021520
    Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.
    Type: Application
    Filed: July 23, 2010
    Publication date: January 27, 2011
    Inventors: Sangamesh BADIGER, Murali CHEBROLU, Mathias FREDERIKSEN, Philipp HOLZER, Konstanze HURTH, Rainer Martin LUEOEND, Rainer MACHAUER, Henrik MOEBITZ, Ulf NEUMANN, Rita RAMOS, Heinrich RUEEGER, Marina TINTELNOT-BLOMLEY, Siem Jacob VEENSTRA, Markus VOEGTLE
  • Hydroxamic acid derivatives
    Patent number: 7589091
    Abstract: Novel hydroxamic acid derivatives, e.g., of formula (I), wherein R1, R2, R3 and R4 are as defined, are found to be useful as pharmaceuticals, e.g., for the suppression of TNF release and the treatment of autoimmune and inflammatory diseases, e.g., multiple sclerosis and rheumatoid arthritis. Methods of making the compounds, novel intermediates, and pharmaceutical compositions comprising the compounds are provided.
    Type: Grant
    Filed: April 8, 2003
    Date of Patent: September 15, 2009
    Assignee: Novartis AG
    Inventors: Philipp Janser, Wolfgang Miltz, Ulf Neumann
  • Hydroxamic acid derivatives
    Publication number: 20060063778
    Abstract: Novel hydroxamic acid derivatives, e.g., of formula (I), wherein R1, R2, R3 and R4 are as defined, are found to be useful as pharmaceuticals, e.g., for the suppression of TNF release and the treatment of autoimmune and inflammatory diseases, e.g., multiple sclerosis and rheumatoid arthritis. Methods of making the compounds, novel intermediates, and pharmaceutical compositions comprising the compounds are provided.
    Type: Application
    Filed: April 8, 2003
    Publication date: March 23, 2006
    Inventors: Philipp Janser, Wolfgang Miltz, Ulf Neumann
  • Hydroxamic acid derivatives
    Patent number: 6500983
    Abstract: Novel hydroxamic acid compounds, e.g., of formula I, wherein R1, R2, R3 and R4 are as defined, are found to be useful as pharmaceuticals, e.g., for the suppression of TNF release and the treatment of autoimmune and inflammatory diseases, e.g., multiple sclerosis and rheumatoid arthritis. Methods of making the compounds, novel intermediates, and pharmaceutical compositions comprising the compounds are provided.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: December 31, 2002
    Assignee: Novartis AG
    Inventors: Georg Kottirsch, Ulf Neumann
  • Hydroxamic acid derivatives
    Publication number: 20020038045
    Abstract: Novel hydroxamic acid compounds, e.g.
    Type: Application
    Filed: October 9, 2001
    Publication date: March 28, 2002
    Inventors: Georg Kottirsch, Ulf Neumann